Company news

Armata Pharmaceuticals, Inc. news in 2024

Armata Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP PA02 in Non Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Form 8 K

December 19, 2024

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

November 20, 2024

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Form 8 K

November 13, 2024

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia Form 8 K

November 12, 2024

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

September 6, 2024

Decks in 2024